Skip to main content
Fig. 6 | BMC Pharmacology and Toxicology

Fig. 6

From: Pharmacokinetic/Pharmacodynamic modelling of Saxagliptin and its active metabolite, 5-hydroxy Saxagliptin in rats with Type 2 Diabetes Mellitus

Fig. 6

(a) Observed 5-OH SAX DPP-4 inhibition ratio versus predicted data. The linear line is red and the OV vs. PRE points are black solid square. (b) The PD profiles of 5-OH SAX in T2DM rats following a tail vein dose of 0.5 mg/kg. The blue solid points represent observed DPP-4 inhibitory (n=3). The red solid line represents model fitting curve. (c) The dose-effect curve of 5-OH SAX in T2DM rats. The arrow indicates that the efficacy of the drug shows a downward trend with the time of administration

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us